JP2023510268A5 - - Google Patents
Info
- Publication number
- JP2023510268A5 JP2023510268A5 JP2022541986A JP2022541986A JP2023510268A5 JP 2023510268 A5 JP2023510268 A5 JP 2023510268A5 JP 2022541986 A JP2022541986 A JP 2022541986A JP 2022541986 A JP2022541986 A JP 2022541986A JP 2023510268 A5 JP2023510268 A5 JP 2023510268A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- fgf
- conjugate
- levels
- reduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958580P | 2020-01-08 | 2020-01-08 | |
| US62/958,580 | 2020-01-08 | ||
| PCT/US2021/012530 WO2021142143A1 (en) | 2020-01-08 | 2021-01-07 | Fgf-21 conjugate formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510268A JP2023510268A (ja) | 2023-03-13 |
| JP2023510268A5 true JP2023510268A5 (https=) | 2024-01-16 |
| JP7600244B2 JP7600244B2 (ja) | 2024-12-16 |
Family
ID=74572842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541986A Active JP7600244B2 (ja) | 2020-01-08 | 2021-01-07 | Ｆｇｆ－２１コンジュゲート製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230346957A1 (https=) |
| EP (1) | EP4087612A1 (https=) |
| JP (1) | JP7600244B2 (https=) |
| KR (1) | KR20220125289A (https=) |
| CN (1) | CN115243725A (https=) |
| AR (1) | AR122359A1 (https=) |
| AU (1) | AU2021205912A1 (https=) |
| BR (1) | BR112022013172A2 (https=) |
| CA (1) | CA3167062A1 (https=) |
| IL (1) | IL294534A (https=) |
| MX (1) | MX2022008336A (https=) |
| TW (1) | TW202140074A (https=) |
| WO (1) | WO2021142143A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023538533A (ja) * | 2020-08-07 | 2023-09-08 | ブリストル－マイヤーズ スクイブ カンパニー | 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１ |
| US20240123031A1 (en) * | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| WO2024153195A1 (en) * | 2023-01-18 | 2024-07-25 | Beijing Ql Biopharmaceutical Co., Ltd. | Liquid pharmaceutical compositions of fusion polypeptides and methods of uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| WO2001032678A1 (en) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
| EP2163626A1 (en) | 1999-11-18 | 2010-03-17 | Novartis Vaccines and Diagnostics, Inc. | Human FGF-21 gene and gene expression products |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| US20050176631A1 (en) | 2002-01-15 | 2005-08-11 | Heuer Josef G. | Method for reducing morbidity and mortality in critically ill patients |
| ATE385806T1 (de) | 2003-06-12 | 2008-03-15 | Lilly Co Eli | Fusionsproteine |
| EP2270163A1 (en) | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Muteins of fibroblast growth factor 21 |
| US20090111742A1 (en) | 2004-01-26 | 2009-04-30 | Alexei Kharitonenkov | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
| JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| EP2194064A1 (en) | 2004-05-13 | 2010-06-09 | Eli Lilly & Company | FGF-21 fusion proteins |
| US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| KR100854198B1 (ko) | 2004-09-02 | 2008-08-26 | 일라이 릴리 앤드 캄파니 | 섬유아세포 성장 인자 21의 뮤테인 |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EP1846019A2 (en) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Method for treating cardiovascular disease |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US8034770B2 (en) | 2008-06-04 | 2011-10-11 | Amgen Inc. | FGF21 polypeptides comprising two or more mutations |
| CA2739615C (en) | 2008-10-10 | 2017-12-05 | Amgen Inc. | Fgf21 mutants comprising polyethylene glycol and uses thereof |
| WO2011154349A2 (en) | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| JP2014500248A (ja) * | 2010-11-05 | 2014-01-09 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗糖尿病化合物 |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| US9434788B2 (en) | 2012-07-11 | 2016-09-06 | The United States Of America, As Represented By The Secretary Of Agriculture | Bio-based fiber gums (BFGs) and processes for producing BFGs |
| US10105447B2 (en) * | 2013-03-13 | 2018-10-23 | Elanco Us Inc. | Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide |
| CN114805532A (zh) * | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| KR20250004095A (ko) | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| KR20210027426A (ko) * | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
-
2021
- 2021-01-07 EP EP21704336.3A patent/EP4087612A1/en not_active Withdrawn
- 2021-01-07 CA CA3167062A patent/CA3167062A1/en active Pending
- 2021-01-07 US US17/791,341 patent/US20230346957A1/en active Pending
- 2021-01-07 TW TW110100686A patent/TW202140074A/zh unknown
- 2021-01-07 KR KR1020227026861A patent/KR20220125289A/ko active Pending
- 2021-01-07 JP JP2022541986A patent/JP7600244B2/ja active Active
- 2021-01-07 CN CN202180018382.9A patent/CN115243725A/zh active Pending
- 2021-01-07 WO PCT/US2021/012530 patent/WO2021142143A1/en not_active Ceased
- 2021-01-07 IL IL294534A patent/IL294534A/en unknown
- 2021-01-07 BR BR112022013172A patent/BR112022013172A2/pt not_active Application Discontinuation
- 2021-01-07 MX MX2022008336A patent/MX2022008336A/es unknown
- 2021-01-07 AU AU2021205912A patent/AU2021205912A1/en not_active Abandoned
- 2021-01-07 US US17/143,938 patent/US20220016211A1/en not_active Abandoned
- 2021-01-07 AR ARP210100034A patent/AR122359A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9381247B2 (en) | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain | |
| US8940691B2 (en) | Method for treating metabolic disorders including type 1 and type 2 diabetes mellitus | |
| CN106456717B (zh) | 速效胰岛素组合物 | |
| US8933023B2 (en) | Rapid acting injectable insulin compositions | |
| AU2013249495A1 (en) | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain | |
| JP2023510268A5 (https=) | ||
| US20120178675A1 (en) | Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin | |
| RS59637B1 (sr) | Tretiranje nafld i nash | |
| CN113301889A (zh) | Nafld和nash的联合治疗 | |
| KR20220113436A (ko) | 경구 이뇨제에 불응성인 부종 치료 방법 및 조성물 | |
| EP3268029A1 (en) | Treatment type 2 diabetes mellitus patients | |
| JP2024003211A (ja) | 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 | |
| US20120035103A1 (en) | Method for administration of insulin and pharmaceutical composition thereof | |
| JP2022537042A (ja) | インクレチンミメティックが装填された脂質ナノカプセル | |
| KR20230098144A (ko) | 당뇨병을 치료하기 위한 이온성 액체 제형 | |
| JP2012532852A (ja) | ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物 | |
| JP2021502404A5 (https=) | ||
| WO2022242527A1 (zh) | 一种单克隆抗体-细胞因子融合蛋白制剂 | |
| CN116635023A (zh) | 用于治疗糖尿病的离子液体制剂 | |
| KR20020097033A (ko) | 당뇨병 환자에게서 공복시 당 및 체중 증가를 감소시키는방법 | |
| US20120270778A1 (en) | Compositions and Methods for Non-Invasive Treatment of Chronic Complications of Diabetes | |
| JPH0242027A (ja) | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 | |
| TW202611066A (zh) | Glp-1類似物的醫藥用途 | |
| US20170128542A1 (en) | Non-aqueous glucagon formulations | |
| EA044268B1 (ru) | Способ лечения неалкогольной жировой болезни печени |